Hypertension Device Trials, DES Cost Data Headline ACC 2009 In Orlando
This article was originally published in The Gray Sheet
Executive Summary
Clinical data on minimally invasive treatments for conditions previously treated with drugs or invasive surgery were in the spotlight at the 2009 American College of Cardiology annual scientific sessions
You may also be interested in...
SCAAR Data Shows Edge For Taxus DES In Diabetics; More Studies Needed
Data from a Swedish registry suggest paclitaxel-eluting stents are more effective than their competitors in diabetic patients, but the results need to be confirmed in prospective randomized trials, the authors conclude
SCAAR Data Shows Edge For Taxus DES In Diabetics; More Studies Needed
Data from a Swedish registry suggest paclitaxel-eluting stents are more effective than their competitors in diabetic patients, but the results need to be confirmed in prospective randomized trials, the authors conclude
SCAAR Data Shows Edge For Taxus DES In Diabetics; More Studies Needed
Boston Scientific's Taxus paclitaxel-eluting stents are more effective than their competitors in diabetic patients in the SCAAR registry, but the results need to be confirmed in prospective randomized trials, the authors conclude.